Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT), a Chinese veterinary vaccine company specializing in livestock vaccines, announced the full exercise of the over-allotment option in its initial public offering (IPO). The underwriters purchased an additional 225,000 ordinary shares at $4.00 per share. Total gross proceeds from the IPO, including the over-allotment, reached $6.9 million before accounting for underwriting discounts and expenses. Trading of the ordinary shares (ZYBT) commenced on the Nasdaq Capital Market on January 7, 2025.

The IPO proceeds will fund acquisitions of vaccine production companies and research and development (R&D) initiatives.

Kingswood Capital Partners, LLC served as the sole book-running manager. Hunter Taubman Fischer & Li LLC provided U.S. securities counsel to Zhengye, and VCL Law LLP acted as U.S. counsel to Kingswood for the offering.

The SEC declared effective the registration statement (Form F-1, File Number: 333-276436) on December 20, 2024. The offering was conducted solely via a prospectus included in the registration statement. Prospectuses are available from Kingswood at Tower 56, 126 E. 56th Street, Suite 22S, New York, NY 10022, or by calling +1-732-910-9692, and also on the SEC website at .

This press release does not constitute an offer to sell or a solicitation of an offer to buy securities. No offer, solicitation, or sale will occur where prohibited by law.

About Zhengye Biotechnology Holding Limited

Operating primarily through Jilin Zhengye Biological Products Co., Ltd. in Jilin, China, Zhengye Biotechnology Holding Limited researches, develops, manufactures, and sells veterinary vaccines, focusing on livestock. For over two decades, the company has been dedicated to animal health. It offers 44 veterinary vaccines for various animals, distributed across 28 Chinese provinces and exported to Vietnam, Pakistan, and Egypt. The company operates three GMP veterinary vaccine production facilities, with 13 production lines, a quality examination center, and an animal facility for vaccine development. Its workforce includes 49 employees with over ten years of industry experience. For more information, please visit the Company’s website: .

Forward-Looking Statements

This announcement contains forward-looking statements involving risks and uncertainties, based on current expectations regarding future events potentially impacting financial condition, results, strategy, and financial needs. Forward-looking terms such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” and “may” often signal these statements. The Company is not obligated to update forward-looking statements unless required by law. While the Company considers these statements reasonable, actual results may differ significantly. Investors should review other factors in the Company’s registration statement and SEC filings.

For more information, please contact:

Zhengye Biotechnology Holding Limited
Investor Relations Department
Email:

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: